Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8.

Kahma H, Filppula AM, Launiainen T, Viinamäki J, Neuvonen M, Evangelista EA, Totah RA, Backman JT.

Drug Metab Dispos. 2019 Apr;47(4):436-443. doi: 10.1124/dmd.118.085498. Epub 2019 Feb 1.

PMID:
30709838
2.

A sensitive and improved throughput UPLC-MS/MS quantitation method of total cytochrome P450 mediated arachidonic acid metabolites that can separate regio-isomers and cis/trans-EETs from human plasma.

Zeigler M, Whittington D, Sotoodehnia N, Lemaitre RN, Totah RA.

Chem Phys Lipids. 2018 Nov;216:162-170. doi: 10.1016/j.chemphyslip.2018.09.004. Epub 2018 Sep 7.

3.

Regulation of CYP2J2 and EET Levels in Cardiac Disease and Diabetes.

Aliwarga T, Evangelista EA, Sotoodehnia N, Lemaitre RN, Totah RA.

Int J Mol Sci. 2018 Jun 29;19(7). pii: E1916. doi: 10.3390/ijms19071916. Review.

4.

CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity.

Evangelista EA, Lemaitre RN, Sotoodehnia N, Gharib SA, Totah RA.

Drug Metab Dispos. 2018 Apr;46(4):380-386. doi: 10.1124/dmd.117.078840. Epub 2018 Jan 17.

5.

Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in Saccharomyces cerevisiae.

McDonald MG, Ray S, Amorosi CJ, Sitko KA, Kowalski JP, Paco L, Nath A, Gallis B, Totah RA, Dunham MJ, Fowler DM, Rettie AE.

Drug Metab Dispos. 2017 Dec;45(12):1364-1371. doi: 10.1124/dmd.117.078188. Epub 2017 Oct 10.

6.

Enzymatic and free radical formation of cis- and trans- epoxyeicosatrienoic acids in vitro and in vivo.

Aliwarga T, Raccor BS, Lemaitre RN, Sotoodehnia N, Gharib SA, Xu L, Totah RA.

Free Radic Biol Med. 2017 Nov;112:131-140. doi: 10.1016/j.freeradbiomed.2017.07.015. Epub 2017 Jul 19.

7.

The role of cytochrome P450 BM3 phenylalanine-87 and threonine-268 in binding organic hydroperoxides.

Roberts AG, Katayama J, Kaspera R, Ledwitch KV, Le Trong I, Stenkamp RE, Thompson JA, Totah RA.

Biochim Biophys Acta. 2016 Apr;1860(4):669-77. doi: 10.1016/j.bbagen.2015.12.014. Epub 2015 Dec 23.

PMID:
26723172
8.

Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Johnson AL, Edson KZ, Totah RA, Rettie AE.

Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27. Review.

9.

Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.

Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, Totah RA.

Biochem Pharmacol. 2014 Sep 1;91(1):109-18. doi: 10.1016/j.bcp.2014.06.020. Epub 2014 Jun 25.

10.

Activity, inhibition, and induction of cytochrome P450 2J2 in adult human primary cardiomyocytes.

Evangelista EA, Kaspera R, Mokadam NA, Jones JP 3rd, Totah RA.

Drug Metab Dispos. 2013 Dec;41(12):2087-94. doi: 10.1124/dmd.113.053389. Epub 2013 Sep 10.

11.

Quantitation of zoledronic acid in murine bone by liquid chromatography coupled with tandem mass spectrometry.

Raccor BS, Sun J, Lawrence RF, Li L, Zhang H, Somerman MJ, Totah RA.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Sep 15;935:54-60. doi: 10.1016/j.jchromb.2013.07.019. Epub 2013 Jul 27.

12.

Cytochrome P450s: new insights and relevance to medicinal chemistry and drug discovery.

Totah RA.

Curr Top Med Chem. 2013;13(12):1363. No abstract available.

PMID:
23688129
13.

OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.

Tamraz B, Fukushima H, Wolfe AR, Kaspera R, Totah RA, Floyd JS, Ma B, Chu C, Marciante KD, Heckbert SR, Psaty BM, Kroetz DL, Kwok PY.

Pharmacogenet Genomics. 2013 Jul;23(7):355-64. doi: 10.1097/FPC.0b013e3283620c3b.

14.

Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.

Lee CA, Jones JP 3rd, Katayama J, Kaspera R, Jiang Y, Freiwald S, Smith E, Walker GS, Totah RA.

Drug Metab Dispos. 2012 May;40(5):943-51. doi: 10.1124/dmd.111.043505. Epub 2012 Feb 10.

15.

Cytochrome P450BM-3 reduces aldehydes to alcohols through a direct hydride transfer.

Kaspera R, Sahele T, Lakatos K, Totah RA.

Biochem Biophys Res Commun. 2012 Feb 17;418(3):464-8. doi: 10.1016/j.bbrc.2012.01.040. Epub 2012 Jan 18.

PMID:
22281497
16.

Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo.

Raccor BS, Claessens AJ, Dinh JC, Park JR, Hawkins DS, Thomas SS, Makar KW, McCune JS, Totah RA.

Drug Metab Dispos. 2012 Jan;40(1):54-63. doi: 10.1124/dmd.111.039347. Epub 2011 Oct 5.

17.

Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5.

Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA.

Biochem Pharmacol. 2011 Sep 15;82(6):681-91. doi: 10.1016/j.bcp.2011.06.027. Epub 2011 Jun 24.

18.

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

Marciante KD, Durda JP, Heckbert SR, Lumley T, Rice K, McKnight B, Totah RA, Tamraz B, Kroetz DL, Fukushima H, Kaspera R, Bis JC, Glazer NL, Li G, Austin TR, Taylor KD, Rotter JI, Jaquish CE, Kwok PY, Tracy RP, Psaty BM.

Pharmacogenet Genomics. 2011 May;21(5):280-8. doi: 10.1097/FPC.0b013e328343dd7d.

19.

Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

Kaspera R, Naraharisetti SB, Tamraz B, Sahele T, Cheesman MJ, Kwok PY, Marciante K, Heckbert SR, Psaty BM, Totah RA.

Pharmacogenet Genomics. 2010 Oct;20(10):619-29. doi: 10.1097/FPC.0b013e32833ecace.

20.

Human liver expression of CYP2C8: gender, age, and genotype effects.

Naraharisetti SB, Lin YS, Rieder MJ, Marciante KD, Psaty BM, Thummel KE, Totah RA.

Drug Metab Dispos. 2010 Jun;38(6):889-93. doi: 10.1124/dmd.109.031542. Epub 2010 Feb 26.

Supplemental Content

Loading ...
Support Center